INTRODUCTION: The electrophysiological consequences of mesenchymal stem cell (MSC) therapy in ischemic heart disease have not been fully understood. METHODS: Swine myocardial infarction (MI) model by intracoronary balloon occlusion received MSC solution or 0.9% NaCl. Six weeks later, heart rate turbulence (HRT), dispersion of action potential durations (APD) and repolarization time (RT) (APDd and RTd), slope of APD reconstitution curve and programmed electrical stimulation were used to evaluate the ventricular arrhythmic risks. RESULTS: MSC treatment could significantly ameliorate the abnormal HRT, APD(90), APDd, RT and RTd. The slope of APD reconstitution curve in MSC group was higher than control group but lower than MI group. MSC therapy markedly reduced inducible malignant ventricular arrhythmias (VAs), and improved impaired cardiac performances and cardiac fibrosis. CONCLUSIONS: This study provides strong evidence that MSC infusion via intracoronary route does not cause VAs but tends to reduce the risk of malignant VAs.
INTRODUCTION: The electrophysiological consequences of mesenchymal stem cell (MSC) therapy in ischemic heart disease have not been fully understood. METHODS:Swinemyocardial infarction (MI) model by intracoronary balloon occlusion received MSC solution or 0.9% NaCl. Six weeks later, heart rate turbulence (HRT), dispersion of action potential durations (APD) and repolarization time (RT) (APDd and RTd), slope of APD reconstitution curve and programmed electrical stimulation were used to evaluate the ventricular arrhythmic risks. RESULTS: MSC treatment could significantly ameliorate the abnormal HRT, APD(90), APDd, RT and RTd. The slope of APD reconstitution curve in MSC group was higher than control group but lower than MI group. MSC therapy markedly reduced inducible malignant ventricular arrhythmias (VAs), and improved impaired cardiac performances and cardiac fibrosis. CONCLUSIONS: This study provides strong evidence that MSC infusion via intracoronary route does not cause VAs but tends to reduce the risk of malignant VAs.
Authors: Jason D Stroud; Catalin F Baicu; Mary A Barnes; Francis G Spinale; Michael R Zile Journal: Am J Physiol Heart Circ Physiol Date: 2002-06 Impact factor: 4.733
Authors: T Ohara; K Ohara; J M Cao; M H Lee; M C Fishbein; W J Mandel; P S Chen; H S Karagueuzian Journal: Circulation Date: 2001-03-13 Impact factor: 29.690
Authors: Philippe Menasché; Albert A Hagège; Jean-Thomas Vilquin; Michel Desnos; Eric Abergel; Bruno Pouzet; Alain Bel; Sorin Sarateanu; Marcio Scorsin; Ketty Schwartz; Patrick Bruneval; Marc Benbunan; Jean-Pierre Marolleau; Denis Duboc Journal: J Am Coll Cardiol Date: 2003-04-02 Impact factor: 24.094
Authors: Matthew J Price; Chung-Chuan Chou; Malka Frantzen; Takashi Miyamoto; Saibal Kar; Steve Lee; Prediman K Shah; Bradley J Martin; Michael Lill; James S Forrester; Peng-Sheng Chen; Raj R Makkar Journal: Int J Cardiol Date: 2005-10-24 Impact factor: 4.164
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: Zhi-Qing Zhao; Cullen D Morris; Jason M Budde; Ning-Ping Wang; Satoshi Muraki; He-Ying Sun; Robert A Guyton Journal: Cardiovasc Res Date: 2003-07-01 Impact factor: 10.787
Authors: Eric G Schmuck; Jill M Koch; Timothy A Hacker; Charles R Hatt; Michael T Tomkowiak; Karl K Vigen; Nicholas Hendren; Cathlyn Leitzke; Ying-Qi Zhao; Zhanhai Li; John M Centanni; Derek J Hei; Denise Schwahn; Jaehyup Kim; Peiman Hematti; Amish N Raval Journal: J Cardiovasc Transl Res Date: 2015-09-15 Impact factor: 4.132